Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NVX-CoV2540

Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by NOVAVAX

Phase 3 Most advanced trial (none active)

NVAX Developer

1 Registered trials

What is NVX-CoV2540?

NVX-CoV2540 is a protein subunit vaccine containing recombinant SARS-CoV-2 spike protein (rS) formulated with Matrix-M adjuvant. It is administered by intramuscular injection and is studied for prevention of COVID-19 and SARS-CoV-2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Recombinant protein vaccine)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: immune_activation
Therapy area: Infectious disease
Developer: NOVAVAX (NVAX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05372588	Phase 3	COVID-19	Completed	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19SARS CoV 2 Infection

More from NOVAVAX

CIC Vaccine Phase 3 EBOV GP Vaccine Phase 1 Fluzone HD Phase 2/3 ICC Vaccine Phase 1/2 NanoFlu Phase 3 NVX-CoV2372 Phase 2 NVX-CoV2373 Phase 3 NVX-CoV2515 Phase 3 NVX-CoV2601 Phase 2/3 NVX-CoV2705 Phase 3 qNIV Vaccine Phase 2 SARS-CoV-2 rS Phase 1/2

Sources

ClinicalTrials.gov NCT05372588

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind NVX-CoV2540

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z